Medical/Pharmaceuticals
Endogenex™ Announces First Patient Enrolled in the ReCET Clinical Study
Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes MINNEAPOLIS, Oct. 15, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company focused on improving outcomes for patients with type 2 diabetes (T2D), t...
2024-10-15 19:32
931
Clarivate Repeats Success in Nobel Prize Predictions with Eight New Winners Identified by Citation Laureates Program
83 Citation Laureates named by the Institute for Scientific Information have received a Nobel Prize since 2002 LONDON, Oct. 15, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the success of its annualCitation Laureates™ p...
2024-10-15 15:00
1092
Aidoc and Integral Diagnostics (IDX) Expand AI Partnership in Australia and New Zealand
Aidoc's AI technology enhances radiology services at IDX, significantly improving patient care and service and well-placed to support the upcoming National Lung Cancer Screening Program. MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Aidoc, a global pioneer in clinical AI solutions, today a...
2024-10-15 11:28
1168
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. * PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney...
2024-10-15 09:51
1211
CooperVision to Host 4th Asia-Pacific Myopia Management Symposium in Seoul, South Korea
Held in partnership with the Korean Association of Paediatric Ophthalmology and
Strabismus (KAPOS), the event will focus on advancing paediatric myopia
management and shaping the future of eye health across the region.
SINGAPORE, Oct. 15, 2024 /PRNewswire/ -- CooperVision
2024-10-15 09:00
3439
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
Highlights * United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence (BCR), AMPLIFY. * The positive results of the completed COBRA and PROPELLER trials,...
2024-10-14 21:02
1744
Metabolon Launches New "Guide to Multiomics" and Accompanying Multiomics Webinar
Metabolon's new multiomics guide and webinar demystify complex omics technologies and illuminate how integrated multiomics is transforming life science research MORRISVILLE, N.C., Oct. 14, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wid...
2024-10-14 21:00
1121
Vivance Completes Pre-Pivotal Trial of Wearable Dialysis Device; Results to be Shared at ASN Kidney Week 2024
SINGAPORE, Oct. 14, 2024 /PRNewswire/ -- Vivance, a leader in kidney care innovations, is proud to announce that the next trial phase of the wearable peritoneal dialysis (PD) device, Viva Kompact, has successfully concluded. The study was conducted at Singapore General Hospital (SGH),Singapore. T...
2024-10-14 21:00
1827
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...
2024-10-14 20:11
1418
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...
2024-10-14 19:00
1630
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...
2024-10-14 19:00
1551
Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina, which recently expanded into the U.S. market following its U.S. FDA 510(k) clea...
2024-10-14 17:00
917
BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)
SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place fromOctober 23 to 27 in San Di...
2024-10-14 15:38
1480
Novotech Awarded Frost & Sullivan's 2024 Global Company of the Year Award for Its Leadership and Excellence in Biotech CRO Services
Novotech's innovative full-service approach accelerates clinical development with advanced analytics, diverse global patient access, and specialized technology. SAN ANTONIO, Oct. 14, 2024 /PRNewswire/ -- Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research or...
2024-10-14 12:30
1123
Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX
HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Zhejiang Taimei Medical Technology Co., Ltd. (the "Company"; Stock code: 2576.HK) has announced that the shares have started to be traded on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code "2576" since today. The Company sai...
2024-10-14 10:18
1194
Modern Meadow Appoints David Williamson as CEO
With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...
2024-10-14 09:00
1028
Modern Meadow Appoints David Williamson as CEO
With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...
2024-10-14 09:00
1276
Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis
News Summary: * Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders. * Novel digestion enzymes deliver complete RNA sequenc...
2024-10-14 08:00
1530
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...
2024-10-13 20:27
3355
Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...
2024-10-13 16:04
2035
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8703
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5845
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5183